Welcome to our dedicated page for Staar Surg SEC filings (Ticker: STAA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The STAAR Surgical Company (NASDAQ: STAA) SEC filings page on Stock Titan brings together the company’s official disclosures from the U.S. Securities and Exchange Commission. STAAR is a medical device manufacturer focused on ophthalmic surgery, and its filings provide detailed information on its implantable intraocular lens business, corporate actions, and governance.
Investors can review Current Reports on Form 8-K in which STAAR reports material events, such as the August 2025 Agreement and Plan of Merger with Alcon, subsequent amendments, the go-shop process, adjournments of special meetings of stockholders, and later communications about the failure to obtain shareholder approval and the intended termination of the merger agreement. Other 8-K filings describe litigation related to the merger proxy statement, preliminary and final financial results, and leadership changes, including the appointment of a Chief Financial Officer and the creation of a Capital Stewardship Committee of the Board.
Filings also confirm that STAAR’s common stock is listed on Nasdaq under the symbol STAA and document how the proposed merger, if completed, would have affected listing status and registration. By reading these documents, users can trace the evolution of STAAR’s strategic transaction with Alcon, the role of major shareholders in the process, and the company’s decision to remain a standalone, publicly traded entity after the merger was not approved.
On Stock Titan, STAAR’s SEC filings are updated as new documents are released on EDGAR. AI-powered tools summarize lengthy filings such as 8-Ks and related exhibits, helping users quickly identify key terms, conditions, and outcomes without reading every page. This makes it easier to track transaction terms, board and management changes, and other disclosures that shape the outlook for STAA within the ophthalmic medical device industry.
BlackRock, Inc. amended a Schedule 13G to report beneficial ownership of 6,507,911 shares of STAAR SURGICAL CO common stock, representing 13.1% of the class as of 03/31/2026.
The filing attributes 6,453,653 shares of sole voting power and lists iShares Core S&P Small-Cap ETF as a holder with more than 5% interest in the issuer’s common stock. The amendment is signed by a Managing Director on 04/24/2026.
Madison Avenue group reports beneficial ownership of 2,854,710 shares of STAAR SURGICAL common stock as of April 20, 2026. The filing states this equals approximately 5.8% of the outstanding common stock based on 49,512,749 shares outstanding as of February 27, 2026. The Schedule 13G lists Madison Avenue International LP and affiliated entities and individuals (including Eli Samaha) as reporting persons with shared voting and dispositive power over the 2,854,710 shares.
STAAR Surgical Company released preliminary results showing strong first quarter 2026 momentum. Net sales for the quarter ended April 3, 2026 are expected to exceed $90 million, up sharply from $42.6 million in the first quarter of 2025, driven mainly by growth in China and continued double-digit growth in the Americas.
The company cites a significantly improved cost structure and expects a meaningful improvement in adjusted EBITDA for the quarter. Management also notes that geopolitical and macroeconomic challenges, particularly in parts of the Middle East, EMEA and APAC, have weighed on sales there and could continue to do so. STAAR plans to report full first quarter 2026 results and file its 10-Q in early May 2026.
STAAR Surgical Co filing: an amended Schedule 13G/A from The Vanguard Group reports 0 shares beneficially owned and 0% of common stock. The filing states Vanguard completed an internal realignment on January 12, 2026 and will report certain subsidiaries separately in reliance on SEC Release No. 34-39538.
The filing lists Vanguard's address and is signed by Ashley Grim, Head of Global Fund Administration, dated 03/27/2026.
ANDREWS DEBORAH J reported acquisition or exercise transactions in this Form 4 filing.
STAAR Surgical granted Interim Co-CEO and CFO Deborah J. Andrews 39,809 restricted stock units (RSUs) on March 13, 2026 as an annual equity award. Each RSU represents one share of common stock and vests in three equal installments through March 13, 2029.
STAAR Surgical’s interim co-CEO and president & COO Warren Foust reported equity compensation activity, mainly from restricted stock units (RSUs). On March 13, 2026, he received a grant of 45,117 RSUs, which will vest in three equal annual installments starting in 2027.
On March 12 and 14, 2026, previously granted RSUs vested and were converted into common stock through option code M transactions, totaling 37,500 shares acquired. Following these events, he directly held 63,588 shares of common stock and 45,117 RSUs subject to future vesting.
STAAR Surgical’s Chief Development Officer Magda Michna reported several equity compensation events. On March 13, 2026, she received a grant of 33,838 restricted stock units (RSUs), which are scheduled to vest in three equal tranches in 2027, 2028, and 2029.
On March 12 and 14, 2026, previously granted RSUs vested and were converted into a total of 23,773 shares of common stock. In connection with these vestings, the company withheld 2,216 shares at $18.39 and 6,313 shares at $18.84 to cover tax obligations, which is recorded as a disposition but not an open‑market sale. Following these transactions, Michna directly holds 29,668 shares of common stock, along with RSUs that remain subject to future vesting.
Broadwood Partners, Broadwood Capital and related individuals updated their ownership in STAAR Surgical Company’s common stock. Broadwood Partners and Broadwood Capital each report beneficial ownership of 16,123,842 shares, representing 32.6% of the 49,512,749 shares outstanding. Neal C. Bradsher may be deemed to beneficially own 16,149,742 shares, also 32.6%, through personal holdings and Broadwood Partners, while Richard T. LeBuhn reports 21,286 shares, or 0.0% of the class.
The amendment primarily reflects changes in beneficial ownership percentages and the fact that LeBuhn will cease to be a reporting person following this filing. The group continues to review its investment, may buy or sell shares over time, and remains in contact with management and other shareholders about ways to create additional shareholder value, but discloses no specific current plans for major corporate actions.
Broadwood Partners, L.P., a more-than-10% owner and director affiliate of STAAR Surgical, reported a series of open-market purchases of Common Stock. Between March 11 and March 13, Broadwood Partners bought a total of 670,213 shares at weighted average prices ranging from about $17.18 to $18.84 per share, with specific daily averages of $17.5217, $18.1154, and $18.6150.
After these transactions, Broadwood Partners directly owned 16,123,842 shares of STAAR Surgical Common Stock. The filing notes that these securities are directly owned by Broadwood Partners and may be deemed indirectly beneficially owned by Broadwood Capital, Inc., as its general partner, and by Neal C. Bradsher, as President of Broadwood Capital. Each reporting person disclaims beneficial ownership beyond their economic interest. A separate holding entry shows 25,900 shares directly owned by Neal C. Bradsher.
STAAR Surgical director and 10% owner Neal C. Bradsher received an option grant to purchase 7,524 shares of common stock at an exercise price of $18.46 per share. The options expire on March 5, 2036 and are held directly.
The options will vest and become exercisable on the earlier of June 18, 2026 or the date of the company’s 2026 annual shareholder meeting, subject to his continuous service as a director. The grant was made on March 6, 2026 as director compensation under STAAR Surgical’s Amended and Restated Omnibus Equity Incentive Plan. Following this grant, Bradsher holds 7,524 options to purchase common stock.